Francesco Rodeghiero

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8259882/publications.pdf

Version: 2024-02-01

109 papers	12,541 citations	53794 45 h-index	28297 105 g-index
114 all docs	114 docs citations	114 times ranked	7347 citing authors

#	Article	IF	Citations
1	Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood, 2009, 113, 2386-2393.	1.4	2,128
2	International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, 2010, 115, 168-186.	1.4	1,802
3	Hydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis. New England Journal of Medicine, 1995, 332, 1132-1137.	27.0	787
4	ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. Journal of Thrombosis and Haemostasis, 2010, 8, 2063-2065.	3.8	607
5	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Advances, 2019, 3, 3780-3817.	5.2	593
6	Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia. New England Journal of Medicine, 2010, 363, 1889-1899.	27.0	374
7	Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood, 2007, 109, 112-121.	1.4	364
8	The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. Journal of Thrombosis and Haemostasis, 2005, 3, 2619-2626.	3.8	317
9	Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica, 2008, 93, 372-380.	3.5	316
10	Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood, 2014, 124, 2930-2936.	1.4	268
11	Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood, 2007, 109, 1401-1407.	1.4	249
12	Thrombopoietin receptor agonists: ten years later. Haematologica, 2019, 104, 1112-1123.	3.5	219
13	The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood, 2009, 114, 3167-3172.	1.4	216
14	Activated Protein C Resistance and Factor V Leiden Mutation Are Independent Risk Factors for Venous Thromboembolism. Annals of Internal Medicine, 1999, 130, 643.	3.9	199
15	Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood, 2008, 111, 3531-3539.	1.4	187
16	Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood, 2013, 121, 2596-2606.	1.4	179
17	Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation. Journal of Clinical Oncology, 2013, 31, 1442-1449.	1.6	167
18	Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD). Blood, 2008, 111, 4979-4985.	1.4	148

#	Article	IF	Citations
19	Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica, 2003, 88, 94-108.	3.5	141
20	Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica, 2011, 96, 1831-1837.	3.5	118
21	Is <scp>ITP</scp> a thrombophilic disorder?. American Journal of Hematology, 2016, 91, 39-45.	4.1	114
22	Thrombosis associated with angiogenesis inhibitors. Best Practice and Research in Clinical Haematology, 2009, 22, 115-128.	1.7	100
23	Shortâ€and longâ€term risks of splenectomy for benign haematological disorders: should we revisit the indications?. British Journal of Haematology, 2012, 158, 16-29.	2.5	99
24	Inconsistency of Association between Type 1 von Willebrand Disease Phenotype and Genotype in Families Identified in an Epidemiological Investigation. Thrombosis and Haemostasis, 1999, 82, 1065-1070.	3.4	98
25	Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica, 2013, 98, 875-880.	3.5	97
26	Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatmentâ€related risk factors. Journal of Thrombosis and Haemostasis, 2014, 12, 1266-1273.	3.8	95
27	Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood, 2008, 111, 1110-1116.	1.4	93
28	Autoimmune cytopenias in chronic lymphocytic leukemia. American Journal of Hematology, 2014, 89, 1055-1062.	4.1	93
29	Longâ€term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. European Journal of Haematology, 2013, 91, 423-436.	2.2	90
30	Prospective Multicenter Study on Subcutaneous Concentrated Desmopressin for Home Treatment of Patients with von Willebrand Disease and Mild or Moderate Hemophilia A. Thrombosis and Haemostasis, 1996, 76, 692-696.	3.4	84
31	Replacement Therapy with Virusâ€"Inactivated Plasma Concentrates in von Willebrand Disease. Vox Sanguinis, 1992, 62, 193-199.	1.5	79
32	How I treat von Willebrand disease. Blood, 2009, 114, 1158-1165.	1.4	79
33	Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. American Journal of Hematology, 2002, 71, 1-6.	4.1	78
34	Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. Blood, 2008, 111, 3998-4003.	1.4	71
35	The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 2016, 101, 115-208.	3.5	67
36	Assessing bleeding in von Willebrand disease with bleeding score. Blood Reviews, 2007, 21, 89-97.	5.7	66

#	Article	IF	Citations
37	Hemostatic complications of angiogenesis inhibitors in cancer patients. American Journal of Hematology, 2008, 83, 862-870.	4.1	62
38	Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. American Journal of Hematology, 2006, 81, 426-431.	4.1	59
39	Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature. Haematologica, 2008, 93, 98-103.	3.5	59
40	A critical appraisal of the evidence for the role of splenectomy in adults and children with <scp>ITP</scp>. British Journal of Haematology, 2018, 181, 183-195.	2.5	58
41	Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). Journal of Thrombosis and Haemostasis, 2007, 5, 715-721.	3.8	54
42	Healthâ€related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. American Journal of Hematology, 2016, 91, 995-1001.	4.1	53
43	The Epidemiology of Inherited Thrombophilia: the VITA Project. Thrombosis and Haemostasis, 1997, 78, 636-640.	3.4	52
44	Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica, 2017, 102, 1342-1351.	3.5	51
45	Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (<scp>ITP</scp>) for up to 1Âyear and in those with chronic <scp>ITP</scp> for more than 1Âyear: a subgroup analysis of integrated data from completed romiplostim studies. British Journal of Haematology, 2019, 185, 503-513.	2.5	49
46	Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thrombosis and Haemostasis, 2011, 105, 647-654.	3.4	44
47	Factor VIII: C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease. British Journal of Haematology, 1995, 89, 147-151.	2.5	43
48	Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia. Annals of Hematology, 2016, 95, 1077-1087.	1.8	43
49	The impact of bleeding history, von Willebrand factor and PFAâ€“100^{Â®} on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDMâ€1VWD. British Journal of Haematology, 2010, 151, 245-251.	2.5	41
50	Treatment of von Willebrand disease. Seminars in Hematology, 2005, 42, 29-35.	3.4	40
51	Homocysteine levels in polycythaemia vera and essential thrombocythaemia. British Journal of Haematology, 1999, 105, 551-555.	2.5	39
52	Is splenectomy still the gold standard for the treatment of chronic ITP?. American Journal of Hematology, 2008, 83, 91-91.	4.1	39
53	ITP and international guidelines: What do we know, what do we need?. Presse Medicale, 2014, 43, e61-e67.	1.9	39
54	A comparative prospective observational study of children and adults with immune thrombocytopenia: 2â€year followâ€up. American Journal of Hematology, 2018, 93, 751-759.	4.1	38

#	Article	IF	Citations
55	Congenital von Willebrand disease type 1: definition, phenotypes, clinical and laboratory assessment. Best Practice and Research in Clinical Haematology, 2001, 14, 321-335.	1.7	37
56	Bâ€¢cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 32-36.	4.1	36
57	Von Willebrand Factor Antigen Is Less Sensitive than Ristocetin Cofactor for the Diagnosis of Type I von Willebrand Disease -Results Based on an Epidemiological Investigation. Thrombosis and Haemostasis, 1990, 64, 349-352.	3.4	36
58	Firstâ€line therapies for immune thrombocytopenic purpura: reâ€evaluating the need to treat. European Journal of Haematology, 2008, 80, 19-26.	2.2	35
59	The VITA Project: Phenotypic Resistance to Activated Protein C and FV Leiden Mutation in the General Population. Thrombosis and Haemostasis, 1997, 78, 859-863.	3.4	34
60	Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status. Haematologica, 2010, 95, 1230-1232.	3.5	33
61	Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists. Annals of Hematology, 2017, 96, 1421-1434.	1.8	33
62	Treatment of Immune Thrombocytopenia in Adults: The Role of Thrombopoietin-Receptor Agonists. Seminars in Hematology, 2015, 52, 16-24.	3.4	31
63	Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers. American Journal of Hematology, 2018, 93, 58-64.	4.1	31
64	Thrombosis in immune thrombocytopenia â€" current status and future perspectives. British Journal of Haematology, 2021, 194, 822-834.	2.5	31
65	Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. American Journal of Hematology, 2012, 87, 203-204.	4.1	29
66	ITP and thrombosis: an intriguing association. Blood Advances, 2017, 1, 2280-2280.	5.2	29
67	The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells, Molecules, and Diseases, 2012, 48, 68-75.	1.4	28
68	Pregnancy in Women with Type 1 von Willebrand Disease Caused by Heterozygosity for von Willebrand Factor Mutation C1130F. Thrombosis and Haemostasis, 2000, 84, 351-352.	3.4	27
69	Idiopathic thrombocytopenic purpura: an old disease revisited in the era of evidence-based medicine. Haematologica, 2003, 88, 1081-7.	3.5	27
70	Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia. Blood, 2021, 138, 571-583.	1.4	26
71	Immune Thrombocytopenia in Lymphoproliferative Disorders. Hematology/Oncology Clinics of North America, 2009, 23, 1261-1274.	2.2	24
72	Treatment practices in adults with chronic immune thrombocytopenia â€" a European perspective. European Journal of Haematology, 2010, 84, 160-168.	2.2	23

#	Article	IF	Citations
73	Eltrombopag secondâ€line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission offâ€treatment: results of a phase II, multicentre, prospective study. British Journal of Haematology, 2021, 193, 386-396.	2.5	23
74	Current Management of von Willebrand??s Disease. Drugs, 1995, 50, 602-614.	10.9	20
75	Management of immune thrombocytopenia in women: current standards and special considerations. Expert Review of Hematology, 2020, 13, 175-185.	2.2	20
76	The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically highâ€risk patients with chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 289-293.	4.1	19
77	Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines. Leukemia and Lymphoma, 2012, 53, 2262-2268.	1.3	18
78	Desmopressin-induced thrombocytopenia in type i platelet discordant von willebrand disease. American Journal of Hematology, 1993, 43, 5-9.	4.1	17
79	Optimizing treatment of von Willebrand disease by using phenotypic and molecular data. Hematology American Society of Hematology Education Program, 2009, 2009, 113-123.	2.5	17
80	Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 277-282.	4.1	17
81	PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021032.	1.3	17
82	Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: A critical appraisal from literature analysis. Pediatric Blood and Cancer, 2006, 47, 653-656.	1.5	16
83	Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study. Blood, 2019, 134, 1708-1711.	1.4	16
84	Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. American Journal of Hematology, 2013, 88, 955-960.	4.1	14
85	Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome. Annals of Hematology, 2016, 95, 863-870.	1.8	14
86	Thrombotic risk in patients with immune haemolytic anaemia. British Journal of Haematology, 2016, 172, 144-146.	2.5	14
87	Von Willebrand disease: Pathogenesis and management. Thrombosis Research, 2013, 131, S47-S50.	1.7	13
88	Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma. Haematologica, 2002, 87, 1157-64.	3.5	11
89	Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. Expert Review of Hematology, 2020, 13, 1319-1332.	2.2	10
90	Treatment outcome in a cohort of young patients with polycythemia vera. Internal and Emergency Medicine, 2010, 5, 411-413.	2.0	8

#	Article	IF	Citations
91	Advances in the diagnosis and management of type 1 von Willebrand disease. Expert Review of Hematology, 2011, 4, 95-106.	2.2	8
92	Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60Âyears. Thrombosis Research, 2020, 185, 88-95.	1.7	7
93	Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology. Journal of Thrombosis and Haemostasis, 2021, 19, 2348-2354.	3.8	7
94	Identical IGHVâ€Dâ€J gene rearrangement may precede the clinical onset of chronic lymphocytic leukemia by several years. American Journal of Hematology, 2010, 85, 868-871.	4.1	6
95	Flow cytometry in the diagnosis of drugâ€induced thrombocytopenia: Two illustrative cases. American Journal of Hematology, 2008, 83, 326-329.	4.1	5
96	TPOâ€receptor agonists in ITP: A clinician's navigation between scylla and charybdis. American Journal of Hematology, 2012, 87, 943-943.	4.1	5
97	Von Willebrand Disease. , 0, , 51-61.		3
98	Efficacy and Safety of IQYMUNEÂ®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia. Journal of Hematology (Brossard, Quebec), 2018, 7, 87-95.	1.0	3
99	Response:Immune thrombocytopenic purpura: terminology and definitions. Blood, 2009, 114, 2004-2004.	1.4	2
100	Immune thrombocytopenia in myeloid and lymphoid clonal disorders: an intriguing association. Haematologica, 2021, 106, 1231-1233.	3.5	2
101	A Prospective Evaluation of Bleeding Tendency and Efficacy of Antihemorrhagic Treatments in Patients with Increased Von Willebrand Factor (VWF) Clearance (Von Willebrand Disease Vicenza AND C1130F) Tj ETQq1 1 0.784314 rgBT /Ov		
102	Recurrent Venous Thrombosis in Patients with Polycythemia Vera and Essential Thrombocythemia. Clinical Leukemia, 2007, 1, 339-344.	0.2	1
103	Von Willebrand disease. Hematology, 2014, 19, 370-371.	1.5	1
104	A hit to current â€œhitâ€•wisdom: A century later, it's time for a change. American Journal of Hematology, 2017, 92, 727-729.	4.1	1
105	The Incidence of Chronic Lymphocytic Leukemia in the General Population.. Blood, 2004, 104, 2809-2809.	1.4	1
106	The revival of clinical wisdom: The case of oral anticoagulation management. American Journal of Hematology, 2009, 84, 546-547.	4.1	0
107	The expert in hemostasis and thrombosis in the Italian health system: role and requirements for a specific clinical and laboratory expertise. Italian Journal of Medicine, 2013, 7, 71.	0.3	0
108	Inhibitor development: The last enemy to be defeated in hemophilia A and B. American Journal of Hematology, 2014, 89, 569-570.	4.1	0

#	Article	IF	Citations
109	Cerebral microbleeds in ITP: alarming or innocent?. Blood, 2020, 136, 2842-2844.	1.4	0